<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794880</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-MOSKOP-MABD</org_study_id>
    <nct_id>NCT05794880</nct_id>
  </id_info>
  <brief_title>MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing</brief_title>
  <official_title>Matched Unrelated Donor and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha/Beta T-Cell and B-Cell Depletion for Patients With Hematologic Malignancies With Targeted ATG Dosing Pilot Study, IDE 13641</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm pilot study for patients with hematologic malignancies receiving&#xD;
      unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the&#xD;
      CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with&#xD;
      individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free&#xD;
      survival&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2023</start_date>
  <completion_date type="Anticipated">May 2032</completion_date>
  <primary_completion_date type="Anticipated">May 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate incidence and extent of aGVHD and engraftment in patients receiving alpha/beta T cell depleted and CD19+ B cell depleted stem cell transplant with individualized ALC-based dosing of ATG</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate incidence of chronic GVHD</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate time to platelet engraftment</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess incidence of viral infections</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate incidence of relapse/progressive disease</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate incidence of treatment-related mortality (TRM).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate overall and relapse free survival (RFS) at 1 year</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assess tempo of CD4+ T cell reconstitution.</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assess tempo of immune reconstitution.</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assess ATG exposure using pre- and post- HCT AUC estimates using ATG dosing module</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Myelodysplasia</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Chronic Myelogenous Leukemia - Chronic Phase</condition>
  <condition>Chronic Myelogenous Leukemia, Accelerated Phase</condition>
  <condition>Chronic Myelogenous Leukemia With Crisis of Blast Cells</condition>
  <condition>Biphenotypic Acute Leukemia</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>Burkitt Leukemia</condition>
  <condition>Lymphoma After Relapse</condition>
  <condition>Other Malignant Hematologic Diseases in Remission</condition>
  <arm_group>
    <arm_group_label>Alpha/Beta T cell depletion (TCD) plus CD19+ depletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alpha beta T cell and B cell depleted allogeneic transplantation with individualized dosing of ATG for patients with hematologic malignancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)</intervention_name>
    <description>Participants in this study will receive a blood stem cell transplant, which will use an investigational device called the CliniMACs device to remove alpha/beta T cells and B cells from the blood cells collected from the donor. This is called T cell depletion and B cell depletion.</description>
    <arm_group_label>Alpha/Beta T cell depletion (TCD) plus CD19+ depletion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age &lt; 25 years. Both genders and all races eligible.&#xD;
&#xD;
          2. Disease eligibility&#xD;
&#xD;
               -  Acute myeloid leukemia, primary or secondary - Disease status: MRD negative (flow&#xD;
                  MRD ≤ 0.1%)&#xD;
&#xD;
               -  Myelodysplasia&#xD;
&#xD;
               -  Acute lymphoblastic leukemia - Disease status: MRD negative&#xD;
&#xD;
               -  Chronic myelogenous leukemia - Disease status: chronic phase, accelerated phase&#xD;
                  or blast crisis now in second chronic phase&#xD;
&#xD;
               -  Mixed lineage or biphenotypic acute leukemia- Disease status: MRD negative&#xD;
&#xD;
               -  Lymphoblastic lymphoma - Disease status: in remission&#xD;
&#xD;
               -  Burkitt's lymphoma/leukemia - Disease status: in remission&#xD;
&#xD;
               -  Lymphoma after relapse - Disease status: in remission&#xD;
&#xD;
               -  Other malignant hematologic diseases in remission (to be approved by PI)&#xD;
&#xD;
          3. Karnofsky Performance Status ≥ 60% for patients 16 years and older and Lansky Play&#xD;
             Score ≥ 60 for patients under 16 years of age (Appendix 1)&#xD;
&#xD;
          4. Evaluation of organ status as per MCW BMT SOP&#xD;
&#xD;
          5. Infectious disease criteria: No active untreated infection. Patients with possible&#xD;
             fungal infections must have had at least 2 weeks of appropriate anti-fungal&#xD;
             antibiotics and be asymptomatic.&#xD;
&#xD;
          6. Signed consent by parent/guardian or able to give consent if ≥18 years.&#xD;
&#xD;
          7. Negative pregnancy test for patients capable of childbearing potential&#xD;
&#xD;
          8. Sexually active patients capable of child-bearing potential must agree to use adequate&#xD;
             contraception (diaphragm, birth control pills, injections, intrauterine device [IUD],&#xD;
             surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration&#xD;
             of treatment. Sexually active men must agree to use barrier contraceptive for the&#xD;
             duration of treatment.&#xD;
&#xD;
        Donor Eligibility:&#xD;
&#xD;
          1. Unrelated donor meets National Marrow Donor Program criteria for donation&#xD;
&#xD;
          2. Infectious disease testing&#xD;
&#xD;
          3. MCW BMT procedures apply for determining donor eligibility, including donor screening&#xD;
             and testing for relevant communicable disease agents and diseases.&#xD;
&#xD;
          4. Only Peripheral blood stem cells will be used for stem cell source on this study&#xD;
             therefore donor must be willing to undergo G-CSF mobilization and stem cell apheresis.&#xD;
             Donor matching. High resolution typing at all loci to be performed.&#xD;
&#xD;
          5. Unrelated Donor:&#xD;
&#xD;
             a. HLA typing of at least 10 alleles is required. Donor must be matched at 9/10 or&#xD;
             10/10 alleles (HLA A, B, C, DRB1, DQB1).Donor and collection center willing to undergo&#xD;
             mobilization and apheresis&#xD;
&#xD;
          6. Haploidentical Related Donor:&#xD;
&#xD;
               1. Haploidentical parent or other related donor: Minimum match level full&#xD;
                  haploidentical (at least 5/10; HLA A, B, C, DRB1, DQB1 alleles), but use of&#xD;
                  haploidentical donors with extra matches (e.g. 6, 7, or 8/10) encouraged.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who do not meet disease, organ, or infectious criteria.&#xD;
&#xD;
          2. No suitable donor&#xD;
&#xD;
          3. Pregnant or lactating patients are ineligible as many of the medications used in this&#xD;
             protocol could be harmful to unborn children and infants&#xD;
&#xD;
          4. Receiving concomitant chemotherapy, radiation therapy; immunotherapy or other&#xD;
             anti-cancer therapy for treatment of disease other than is specified in the protocol.&#xD;
             Maintenance or other post-HCT therapy can be considered after discussion with the&#xD;
             study PI.&#xD;
&#xD;
          5. Participating in a concomitant Phase 1 or 2 study involving treatment of disease&#xD;
&#xD;
          6. Active malignancy other than eligible disease specified in the protocol. Patients with&#xD;
             prior malignancy can be eligible as long as at least 1 year post treatment for that&#xD;
             malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meredith Beversdorf, RN</last_name>
    <phone>414-266-5891</phone>
    <email>mbeversdorf@childrenswi.org</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 8, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Amy Moskop</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

